Blood rheology in deep venous thrombosis - Relation to persistent and transient risk factors

Thrombosis Research

Volumn 107, Issue 3-4, 2002, Pages 101-107

  Alt, Elisabeth ^a   Banyai, Susanne ^a   Banyai, Martin ^a   Koppensteiner, Renate ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Blood rheology; Deep venous thrombosis; Persistent risk factors; Recurrent thromboembolism; Transient risk factors

Indexed keywords

ADRENALIN; FIBRINOGEN; BIOLOGICAL MARKER;

ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; ERYTHROCYTE AGGREGATION; FIBRINOGEN BLOOD LEVEL; HEMATOCRIT; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE AGGREGATION; TIME; ADULT; AGED; BLOOD; BLOOD EXAMINATION; CASE CONTROL STUDY; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD VISCOSITY; CASE-CONTROL STUDIES; ERYTHROCYTE AGGREGATION; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HEMATOLOGIC TESTS; HEMORHEOLOGY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; TIME FACTORS; VENOUS THROMBOSIS;

EID: 0037104677     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00302-X     Document Type: Article

References (29)

1. Martinelli I. Risk factors in venous thromboembolism. Thromb. Haemost. 86(1):2001;395-403.
2. Hansson P.O., Sorbo J., Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch. Intern. Med. 160(6):2000;769-774.
3. Prandoni P.et al. The long-term clinical course of acute deep venous thrombosis. Ann. Intern. Med. 125(1):1996;1-7.
4. Sudlow M.F., Campbell I.A., Angel J.H., Bentley P., Fennerty A.G., Prescott R.J., Routledge P.A. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research committee of the British Thoracic Society. Lancet. 340(8824):1992;873-876.
5. Schulman S.et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N. Engl. J. Med. 332(25):1995;1661-1665.
6. Ouriel K.et al. The anatomy of deep venous thrombosis of the lower extremity. J. Vasc. Surg. 31(5):2000;895-900.
7. Juhan-Vague I.et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb. Haemost. 57(1):1987;67-72.
8. Korninger C.et al. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis. Thromb. Haemost. 52(2):1984;127-130.
9. Virchow R. Thrombose und Embolie. 1910;Verlag von Johann Ambrosius Barth, Germany.
10. Dormandy J.A., Edelman J.B. High blood viscosity: an aetiological factor in venous thrombosis. Br. J. Surg. 60(3):1973;187-190.
11. Pearson T.C., Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 2(8102):1978;1219-1222.
12. Koster T.et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thromb. Haemost. 71(6):1994;719-722.
13. Mira Y.et al. Hemorheological alterations and hypercoagulable state in deep vein thrombosis. Clin. Hemorheol. Microcirc. 19(4):1998;265-270.
14. Chabanel A.et al. Red blood cell aggregability in patients with a history of leg vein thrombosis: influence of post-thrombotic treatment. Br. J. Haematol. 88(1):1994;174-179.
15. Koppensteiner R.et al. Hemorheology in systemic ultrahigh-dose thrombolytic therapy with streptokinase and urokinase. Thromb. Res. 56(2):1989;277-287.
16. Mira Y.et al. Effect of unfractionated sodium heparin at therapeutic doses on the hemorheological parameters of patients with deep vein thrombosis. Clin. Hemorheol. 16(3):1996;277-284.
17. Lensing A.W.A., Prandoni P., Brandjes D.et al. Detection of deep-vein thrombosis by real time B-mode ultrasonography. N. Engl. J. Med. 320:1989;342-345.
18. Hirsh J., Hoak J. Management of deep vein thrombosis and pulmonary embolism. Circulation. 93:1996;2212-2245. [Reference für Durchführung Phlebo].
19. Clauss A. Eine gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 17:1957;235.
20. Inglis T. Clinical measurement of whole-blood viscosity at low shear rates. Clin. Hemorheol. 1:1981;167.
21. Schmid-Schönbein H. New hemorheological techniques for routine laboratory. Clin. Hemorheol. 2:1982;93.
22. Hyers T.M., Agnelli G., Hull D.R., Morris A.T., Samama M., Tapson V.et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 119:2001;176S-193S.
23. Reizenstein P. The haematological stress syndrome. Br. J. Haematol. 43(3):1979;329-334.
24. Chien S. Biphysical behaviour of red cells in suspension. Surgenor D.M. The Red Blood Cell. 1975;2-12 Academic Press, San Francisco.
25. Sevitt S. Pathology and pathogenesis of deep vein thrombi. Tesi M., Dormandy J.A. Superficial and Deep Venous Disorder of the Lower Limbs. 1984;45-48 Edizinoe Panminerva Medica, Turin.
26. Wu K.K., Barnes R.W., Hoak J.C. Platelet hyperaggregability in idiopathic recurrent deep vein thrombosis. Circulation. 53(4):1976;687-691.
27. Hutton B.A., Prins M.H. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Rev. Cochrane Libr. 3:2001.
28. Pinede L.et al. Optimal duration of anticoagulant therapy after an episode of venous thromboembolism. Blood Coagul. Fibrinolysis. 11(8):2000;701-707.
29. Schulman S.et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N. Engl. J. Med. 336(6):1997;393-398.